Merck Stock Forecast for 2023 - 2025 - 2030
Updated on 05/30/2024
Merck Stock Forecast and Price Target
The average price target of $144.00 for Merck's stock set by eleven distinguished analysts in recent weeks would represent a potential upside of approximately 14.38% from the last closing price in May, 2024 if reached by the end of the year. This potential increase is based on a high estimate of $155.00 and a low estimate of $118.00. If you want to buy MRK stock, it might be a good idea to look at its competitors too.
14.38% Upside
Merck Fair Value Forecast for 2023 - 2025 - 2030
In the last four years, Merck's Price has decreased from $80.78 to $0.00 – a 100.00% drop! The next year looks promising for Merck, with analysts predicting Fair Value of $112.74 – an increase of 100.00%. Over the next seven years, experts anticipate that Merck's Fair Value will grow at a rate of 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| LLY Stock Forecast | Eli Lilly and | Outperform |
16
|
$811.53 | Buy/Sell | $636.99 | 8.13% |
| JNJ Stock Forecast | Johnson & Johnson | Outperform |
9
|
$144.44 | Buy/Sell | $174.55 | 17.70% |
| PFE Stock Forecast | Pfizer | Outperform |
2
|
$27.82 | Buy/Sell | $32.87 | 9.53% |
| VRTX Stock Forecast | Vertex Pharmaceuticals Inc | Outperform |
12
|
$441.13 | Buy/Sell | $457.59 | 4.05% |
| REGN Stock Forecast | Regeneron Pharmaceuticals | Outperform |
2
|
$966.49 | Buy/Sell | $961.26 | 8.64% |
Merck Revenue Forecast for 2023 - 2025 - 2030
In the last three years, Merck's Revenue has grown, increasing from $47.99B to $60.12B – a growth of 25.26%. The next year, 16 experts forecast that Merck's Revenue will decrease by 3.38%, reaching $58.09B. In 2030, professionals predict that Merck's Revenue will decrease by 14.39%, reaching $51.46B.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BMY Stock Forecast | Bristol-Myers Squibb | Hold |
2
|
$40.25 | Buy/Sell | $58.15 | 34.16% |
| ZTS Stock Forecast | Zoetis | Outperform |
18
|
$170.80 | Buy/Sell | $220.47 | 27.05% |
| ALNY Stock Forecast | Alnylam Pharmaceuticals Inc | Outperform |
7
|
$146.93 | Buy/Sell | $245.24 | 48.03% |
.jpg)
Merck Dividend per Share Forecast for 2023 - 2025 - 2030
In the last three years, Merck's Dividend per Share has grown by 19.67%, from $2.44 to $2.92. For the next year, analysts are expecting Dividend per Share to reach $3.27 – an increase of 11.99%. Over the next seven years, experts predict that Dividend per Share will grow by 9.59%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BAX Stock Forecast | Baxter International Inc | Hold |
17
|
$33.19 | Buy/Sell | $44.86 | 32.57% |
| VTRS Stock Forecast | Viatris Inc | Hold |
8
|
$10.31 | Buy/Sell | $11.73 | 16.39% |
| UTHR Stock Forecast | United Therapeutics | Outperform |
12
|
$267.72 | Buy/Sell | $284.08 | 12.06% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| CTLT Stock Forecast | Catalent | Hold |
15
|
$53.58 | Buy/Sell | $49.29 | 18.51% |
| CYTK Stock Forecast | Cytokinetics | Outperform |
10
|
$47.86 | Buy/Sell | $87.92 | 77.60% |
| IONS Stock Forecast | Ionis Pharmaceuticals | Outperform |
9
|
$36.45 | Buy/Sell | $55.60 | 64.61% |
Merck EBITDA Forecast for 2023 - 2025 - 2030
In the last three years, Merck's EBITDA has fallen from $19.07B to $8.30B – a 56.49% decrease. For next year, analysts predict EBITDA of $26.32B, which would mean an increase of 217.18%. Over the next seven years, experts predict that Merck's EBITDA will grow at a rate of 119.92%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BCPC Stock Forecast | Balchem | Outperform |
18
|
$149.63 | Buy/Sell | $145.00 | 10.27% |
| MDGL Stock Forecast | Madrigal Pharmaceuticals | Outperform |
4
|
$222.51 | Buy/Sell | $315.92 | 73.48% |
| NEOG Stock Forecast | Neogen | Outperform |
16
|
$13.17 | Buy/Sell | $37.00 | 29.08% |
Merck EBIT Forecast for 2023 - 2025 - 2030
Merck's EBIT has decreased In the last three years, from $15.71B to $4.57B – a 70.95% drop. For next year, analysts predict EBIT of $24.18B, which would mean an increase of 429.70%. Over the next seven years, experts predict that Merck's EBIT will grow at a rate of 327.40%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| CORT Stock Forecast | Corcept Therapeutics | Buy |
16
|
$31.53 | Buy/Sell | $35.67 | 26.86% |
| INDV Stock Forecast | Indivior PLC | Buy |
14
|
£14.10 | Buy/Sell | £28.89 | 119.36% |
| TGTX Stock Forecast | TG Therapeutics | Outperform |
9
|
$16.36 | Buy/Sell | $29.44 | 110.88% |
Merck EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last four years, Merck's EPS has decreased from $5.94 to $0.00 – a 100.00% drop! The next year looks promising for Merck, with analysts predicting EPS of $8.29 – an increase of 100.00%. Over the next seven years, experts anticipate that Merck's EPS will grow at a rate of 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| AMPH Stock Forecast | Amphastar Pharmaceuticals | Outperform |
14
|
$41.64 | Buy/Sell | $69.00 | 48.90% |
| CPRX Stock Forecast | Catalyst Pharmaceuticals | Buy |
16
|
$15.88 | Buy/Sell | $26.20 | 63.73% |
| SUPN Stock Forecast | Supernus Pharmaceuticals | Outperform |
16
|
$26.57 | Buy/Sell | $41.00 | 52.43% |
.jpg)